Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355266 | 0.87 | KDM4E (0.47) | KDM4EMAPTMEN1KMT2A | |
| SCHEMBL15727406 | 0.80 | LOXL2 (0.40) | NCF1LOXL2SSTR4AAK1HTR1A | |
| SCHEMBL6627325 | 0.80 | NCF1 (0.39) | NCF1LOXL2SSTR4AAK1HTR1A | |
| SCHEMBL828159 | 0.80 | GAK (0.55) | NCF1LOXL2HPGDALOX15GAK | |
| SCHEMBL289272 | 0.79 | SSTR4 (0.41) | NCF1LOXL2SSTR4AAK1HTR1A | |
| SCHEMBL27508840 | 0.79 | NCF1 (0.50) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| Iodide SCHEMBL14236731 | 0.79 | GAK (0.54) | NCF1LOXL2HPGDALOX15GAK | |
| Iodide SCHEMBL14236729 | 0.79 | GAK (0.54) | NCF1LOXL2HPGDALOX15GAK | |
| SCHEMBL9431770 | 0.78 | NCF1 (0.54) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL9969420 | 0.76 | SSTR4 (0.49) | NCF1LOXL2SSTR4AAK1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2496234-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| CN-102596200-A | Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors | MERCK PATENT GMBH | 2012-07-18 | — | — | CN | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
| EP-1377554-A1 | ANTAGONISM OF IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES BY 4-AMINOQUINOLINES AND OTHER WEAK BASES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6479504-B1 | USED IN PREVENTATIVE AND THERAPEUTIC TREATMENTS OF AUTOIMMUNE DISEASES AND PHENOMENA, TRANSPLANT REJECTION SUCH AS HOST-VERSUS-GRAFT DISEASE, AND SEPSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-11-12 | — | — | US | disclosed |
| WO-2000076982-A1 | ANTAGONISM OF IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES BY 4-AMINOQUINOLINES AND OTHER WEAK BASES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | TGFBR1, TGFBR2, TGFB1 | NCF1 2279/4885LOXL2 432/4885SSTR4 3656/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | NCF1 2336/4885LOXL2 915/4885SSTR4 2296/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | NCF1 2336/4885LOXL2 915/4885SSTR4 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.